• A review and analysis of the patient's anatomic pathology report relating to TNM staging ("Tumor Node Metastasis"); review of the patient's medical history and risk factors, current condition as well as any co-morbid factors; and complete review of symptoms prior to presentation.
• A review and analysis of the paitent's molecular profiling reports (genomics, proteomics, transcriptomics, immune cell studies) with assistance ordering additional reports from specialty laboratories.
  
• Referrals, at the patient contact's request, to medical oncologists, radiation oncologists, surgical oncologists, radiologists, interventional radiologists, anesthesiologists, and additional specialists relevant to the patient's ongoing care.
• Referrals to support groups that may be of assistance in handling the emotional impact that cancer has on the patient and the patient's family.
• Referrals to ovarian cancer-specific organizations that may be of assistance in addressing insurance issues or employment termination issues (because of diagnosis or disclosure of metastatic disease).
• Review of the nature/amelioration of specific side effects from chemotherapy (such as nausea and neuropathy) as well as from targeted drugs and immunotherapies.
  
• Discussion of the interaction of diet and anticancer drugs based on recent studies.
• Delineation of the symptoms about which the patient should alert her oncologist.
• Discussion of relevant imaging studies.
• Discussion of pain management issues and treatment options that can be addressed with the patient's medical team.
• Explanation of the recommendations given or not given by the patient's physicians; assistance in answering the patient's questions which remain either after or between appointments with the medical team.
• Review of the relevant radiotherapy/interventional radiology options which the patient contact, in turn, may discuss with her medical team.
• Discussion of the relevance of the patient's specific molecular profiling results if the patient is considering screening for available clinical trials so that the patient may explore all options with her medical oncology team.
• Analysis of relevant ovarian cancer clinical trials options as well as the nature and purpose of clinical trials using Remission Coach®.
• Review of relevant ovarian cancer-specific drugs in early development.
• Review of all relevant and complementary and alternative medicine ("CAM") avenues.
• Review of the merits of requesting expanded access/compassionate use/Right to Try for a specific experimental cancer drug, if relevant to the patient's situation.
• Exploration of options that might reduce travel costs for the patient contact, such as Corporate Angels Network, as well as ICAN supporters who have volunteered to host a clinical trials patient in a particular city.

ICAN is currently working on The Karen Ann Jones Ovarian Cancer Clinical Trials Program. We are working to put together a Family and Friends Advisory Council for the The Karen Ann Jones Ovarian Cancer Clinical Trials Program. If interested, please email us at Karen.Jones.Program@askican.org.

If you would like to become involved as a donor and supporter or a member of our Cancer Research Literature team as a Research Team Leader (medical school students, physicians, nurses, and post-docs only please), you may reach us at Karen.Jones.Program@askican.org.

Federal Tax I.D.: EIN 86-0818253 | WA Charities: 37195